Precision oncology relies on the identification of molecular alterations, responsible for tumor
initiation and growth, which are suitable targets of specific inhibitors. The development of …

Lung carcinoma is one of the most common human cancers and is estimated to have an
incidence of approximately 2 million new cases per year worldwide with a 20% mortality …

PURPOSE NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as
potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide …

Introduction: Since the approval of immune checkpoint inhibitors (ICIs), there has been
continuing and significant progress in urothelial cancer (UC) treatment. However, only about …

The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …

The current SARS covid-19 epidemic spread appears to be influenced by ethnical,
geographical and sex-related factors that may involve genetic susceptibility to diseases …

Lung cancer represents an extremely diffused neoplastic disorder with different
histological/molecular features. Among the different lung tumors, non-small-cell lung cancer …

Background The abnormal expression of genes is an essential factor affecting the prognosis
of cancer. RNA modification is a way of regulating post-transcriptional levels, including m 6 …

Background and Objective Compared with tissue biopsy, liquid biopsy is the most preferable
non-invasive promising method in personalized medicine, although it has many limitations …